We have located links that may give you full text access.
Treatment of intractable Menière's disease with intratympanic gentamicin: review of the University of Ottawa experience.
Journal of Otolaryngology 1997 December
OBJECTIVE: Intractable Meniere's disease has traditionally been treated surgically, with either labyrinthectomy, vestibular nerve section, or endolymphatic sac procedures. Another option is the use of intratympanic gentamicin to effect a 'gentamicin labyrinthectomy.' Nedzelski and coworkers have previously reported an 83% complete elimination and 17% substantial reduction in vertigo using this method.
METHOD: We retrospectively reviewed 21 patients treated at our centre with intratympanic gentamicin between 1991 and 1995, all of whom fulfilled the criteria for reporting results in Meniere's therapy described in the American Association of Otolaryngology Committee on Hearing and Equilibrium 1995 guidelines. Our patients are presented using these guidelines, specifically examining four criteria: frequency of vertigo, word recognition, functional level, and hearing threshold.
RESULTS: At 2-year follow-up, 17 of 21 patients (80.9%) had complete elimination of vertigo, with 3 of 21 (14.3%) reporting a 60 to 99% reduction in frequency. Nineteen of 21 patients (90.5%) described themselves as having no impairment secondary to dizziness. Average hearing thresholds and word-recognition scores appear to have both worsened after gentamicin therapy.
CONCLUSION: Intratympanic gentamicin therapy for vertigo in Meniere's disease was shown to be an effective treatment choice, as shown by our results. However, with the reduction of average hearing thresholds and word-recognition scores, patients should be advised of these possible complications as part of informed consent.
METHOD: We retrospectively reviewed 21 patients treated at our centre with intratympanic gentamicin between 1991 and 1995, all of whom fulfilled the criteria for reporting results in Meniere's therapy described in the American Association of Otolaryngology Committee on Hearing and Equilibrium 1995 guidelines. Our patients are presented using these guidelines, specifically examining four criteria: frequency of vertigo, word recognition, functional level, and hearing threshold.
RESULTS: At 2-year follow-up, 17 of 21 patients (80.9%) had complete elimination of vertigo, with 3 of 21 (14.3%) reporting a 60 to 99% reduction in frequency. Nineteen of 21 patients (90.5%) described themselves as having no impairment secondary to dizziness. Average hearing thresholds and word-recognition scores appear to have both worsened after gentamicin therapy.
CONCLUSION: Intratympanic gentamicin therapy for vertigo in Meniere's disease was shown to be an effective treatment choice, as shown by our results. However, with the reduction of average hearing thresholds and word-recognition scores, patients should be advised of these possible complications as part of informed consent.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app